The global lower respiratory tract disease diagnosis and treatment market is anticipated to grow at a CAGR of 7.4% during the forecast period (2023-2030). The prevailing cause of illness and mortality in both children and adults around the globe is lower respiratory tract infections. Some of the major lower respiratory tract infections includes acute bronchitis, pneumonia, acute exacerbations of chronic obstructive pulmonary disease/chronic bronchitis (AECB), and acute exacerbation of bronchiectasis. Numerous research facilities are investigating innovative lung medications for the treatment of critically ill patients suffering with acute respiratory distress syndrome. The lower respiratory tract illness diagnosis and treatment market is being driven forward by a rise in the incidence of chronic respiratory disorders such as occupational lung disease, chronic pulmonary fibrosis, pulmonary hypertension, and asthma. Premature infants, individuals with persistent lung illness of infancy, and people with major congenital heart disease possesses high risk of creating severe Respiratory Syncytial Virus (RSV) infections.
Browse the full report description of “Lower Respiratory Tract Disease Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Condition (Pneumonia, Bronchitis, Tuberculosis, and Others), by Diagnosis (Mucus Samples, Blood Tests, Chest X-Rays, and Pulse Oximetry), and by Treatment (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Analgesics and, Antipyretic Drugs, Bronchodilator Inhaler and Others), and by Category (Over-the-Counter (OTC) and Prescription), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/lower-respiratory-tract-disease-diagnosis-and-treatment-market
Hence, owing to such as increase in number of people suffering with any respiratory issue, the market for its diagnosis and treatment to grow considerably over the forecast period. For instance, in July 2023, the US Food and Drug Administration (FDA) approved Beyfortus (nirsevimab-alip) for the treatment of new borns and children aged 24 months to reduce the chances of causing lower respiratory tract infections by RSV. The aging immune system loses the ability to protect against infections older adults are at greater risk than young adults for serious complications from RSV. Further, in May 2023, the US FDA approved Arexvy (the respiratory syncytial virus vaccine, adjuvants) for preventing generating lower respiratory tract diseases in people aged 60 years and above.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Conditions
o By Diagnosis
o By Treatment
o By Category
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- F. Hoffmann-La Roche Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Co., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Lower Respiratory Tract Disease Diagnosis and Treatment Market Report Segment
By Conditions
By Diagnosis
By Treatment
By Category
Global Lower Respiratory Tract Disease Diagnosis and Treatment Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lower-respiratory-tract-disease-diagnosis-and-treatment-market